This study is testing a combination of three drugs for people with a type of lung cancer called non-small cell lung cancer (NSCLC). These patients have not responded well to previous treatments. The drugs used are: Pembrolizumab, which helps the immune system attack cancer; Ramucirumab, which stops new blood vessels from feeding tumors; and Docetaxel, which stops cancer cells from dividing. Pembrolizumab is a PD-1 checkpoint inhibitor, meaning it helps keep the immune system active against cancer cells. The study aims to see if this new combination works better than current treatments.
- Participation Requirements: Visits every 21 days, with regular check-ins for up to 10 years to monitor the effects.
- Compensation: Details on compensation are not specified, but participants may benefit from potential improvements in their condition.
- Potential Risks: Side effects may occur, and participants will be closely monitored for their safety.
How understandable was the trial content above?
Hard to understand
Easy to understand